Category: Uncategorized

Consolidation of global control AstraZeneca has officially reached an agreement to acquire AbelZeta Pharma’s 50% stake in the development and... Read more

Completion of equity acquisition Harbour BioMed has announced that its wholly owned subsidiary exercised a warrant agreement to acquire common... Read more

Large-scale product portfolio update On January 19, 2026, Qosina officially released its "New Product Preview," showcasing more than 500 newly... Read more

Regulatory recognition On January 19, 2026, the U.S. Food and Drug Administration (FDA) officially granted "Breakthrough Therapy" designation to ianalumab,... Read more

Consolidation of development and commercialization rights On January 19, 2026, AstraZeneca entered into an agreement to acquire AbelZeta’s remaining 50%... Read more

Allegations of monopoly and suppressed competition On January 14, 2026, Strive Compounding Pharmacy (headquartered in Arizona, USA) filed a federal... Read more

Priority status in U.S. tariff policy Despite a lackluster environment for foreign direct investment (FDI) in the UK, the nation's... Read more

Background and medico-political concerns In late 2025, claims from the U.S. administration regarding a potential link between prenatal acetaminophen (Tylenol)... Read more

Strategic collaboration for novel antibody development At the 2026 J.P. Morgan Healthcare Conference, Shanghai Henlius Biotech announced an exclusive global... Read more